MacroGenics, Inc. (NASDAQ:MGNX) – Stock analysts at Leerink Swann boosted their FY2017 earnings estimates for MacroGenics in a research note issued to investors on Wednesday. Leerink Swann analyst M. Schmidt now expects that the biopharmaceutical company will earn ($4.69) per share for the year, up from their prior estimate of ($4.71). Leerink Swann also issued estimates for MacroGenics’ Q4 2017 earnings at ($1.23) EPS and FY2018 earnings at ($4.76) EPS.

A number of other brokerages also recently commented on MGNX. Zacks Investment Research downgraded MacroGenics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 3rd. Morgan Stanley reduced their price objective on MacroGenics from $24.00 to $22.00 and set an “equal weight” rating on the stock in a research report on Monday, May 8th. Cowen and Company reiterated a “buy” rating on shares of MacroGenics in a research report on Friday. ValuEngine downgraded MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Thursday. Finally, BidaskClub downgraded MacroGenics from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Three research analysts have rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $32.40.

ILLEGAL ACTIVITY NOTICE: “MacroGenics, Inc. (NASDAQ:MGNX) to Post FY2017 Earnings of ($4.69) Per Share, Leerink Swann Forecasts” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/07/macrogenics-inc-nasdaqmgnx-to-post-fy2017-earnings-of-4-69-per-share-leerink-swann-forecasts.html.

Shares of MacroGenics (NASDAQ MGNX) opened at 17.28 on Monday. The company’s 50-day moving average price is $17.76 and its 200 day moving average price is $18.87. The stock’s market cap is $635.87 million. MacroGenics has a 12-month low of $15.70 and a 12-month high of $33.30.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by $0.09. MacroGenics had a negative net margin of 1,216.51% and a negative return on equity of 56.81%. The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $15.82 million. During the same quarter in the previous year, the company posted $1.12 EPS. The business’s quarterly revenue was down 97.9% on a year-over-year basis.

In other MacroGenics news, SVP Jon Marc Wigginton sold 5,000 shares of MacroGenics stock in a transaction on Monday, June 5th. The stock was sold at an average price of $20.00, for a total value of $100,000.00. Following the sale, the senior vice president now owns 35,000 shares in the company, valued at $700,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.30% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of MGNX. OppenheimerFunds Inc. increased its stake in MacroGenics by 9.4% in the first quarter. OppenheimerFunds Inc. now owns 3,323,025 shares of the biopharmaceutical company’s stock worth $61,808,000 after buying an additional 286,018 shares in the last quarter. BB Biotech AG increased its stake in MacroGenics by 17.7% in the first quarter. BB Biotech AG now owns 2,260,000 shares of the biopharmaceutical company’s stock worth $42,036,000 after buying an additional 340,000 shares in the last quarter. Vanguard Group Inc. increased its stake in MacroGenics by 3.4% in the first quarter. Vanguard Group Inc. now owns 1,352,864 shares of the biopharmaceutical company’s stock worth $25,163,000 after buying an additional 44,680 shares in the last quarter. State Street Corp increased its stake in MacroGenics by 20.0% in the first quarter. State Street Corp now owns 1,007,211 shares of the biopharmaceutical company’s stock worth $18,732,000 after buying an additional 167,720 shares in the last quarter. Finally, Hood River Capital Management LLC increased its stake in MacroGenics by 17.2% in the first quarter. Hood River Capital Management LLC now owns 563,143 shares of the biopharmaceutical company’s stock worth $10,474,000 after buying an additional 82,691 shares in the last quarter. Institutional investors own 82.34% of the company’s stock.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Earnings History and Estimates for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.